2025 Annual Meeting | C136 - Motor Neuron Disease

Date Tuesday 04/08/25

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Location San Diego Convention Center | 3

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Stephen Goutman, MD, FAAN

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Participants should become familiar with ALS epidemiology, ALS and MND clinical presentations, diagnosis, and clinical management and treatment; and learn about the emerging role of genetic testing in ALS for understanding disease risk and for personalized therapeutics.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:30 AM PDT	Speaker	Diagnosis and Management of ALS Stephen Goutman, MD, FAAN
07:30 AM - 08:00 AM PDT	Speaker	Non-ALS Adult Motor Neuron Diseases Kelly G. Gwathmey, MD
08:00 AM - 08:30 AM PDT	Speaker	ALS Genetic Testing and Results Interpretation Matthew Harms, MD
08:00 AM - 09:00 AM PDT	Q&A	Questions and Answers Stephen Goutman, MD, FAAN, Matthew Harms, MD, Kelly G. Gwathmey, MD

Faculty Disclosures
Stephen Goutman, MD, FAAN	Dr. Goutman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Evidera. The institution of Dr. Goutman has received research support from National Institutes of Health. The institution of Dr. Goutman has received research support from ALS Association. The institution of Dr. Goutman has received research support from CDC. Dr. Goutman has received intellectual property interests from a discovery or technology relating to health care.
Matthew Harms, MD	Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Harms has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Muscular Dystrophy Association. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Invitae. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Variant Bio. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Dr. Harms has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Littlepage Booth. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for O'Connor First. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Searcy Denney. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Ford, Parshall & Baker LLC . The institution of Dr. Harms has received research support from ALS Association. The institution of Dr. Harms has received research support from Ionis. The institution of Dr. Harms has received research support from ALS Finding a Cure. The institution of Dr. Harms has received research support from Target ALS.
Kelly G. Gwathmey, MD	Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Strongbridge. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Gwathmey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals.

��ɫ��

��ɫ��